Header

Novartis is pushing the boundaries of innovation with bold science, seeking to transform lives and striving toward cures for patients.

Working to help extend and improve lives for patients with breast cancer

For more than 30 years, the priority of Novartis has been to deliver innovative targeted therapies for breast cancer that extend and transform patients’ lives as we work toward a cure

Reimagining Hematology

Novartis is deeply committed to transforming the lives of people living with blood cancers and serious life-threatening blood disorders.

 

We believe that anyone living with these conditions has the right to a life free from symptoms and free from disease – this is our vision for the future. 

Learn More
Tumor cells being attacked by CAR-T

Charging forward with next-generation CAR-T cell therapy for people with cancer

We are developing a novel, next-generation CAR-T platform that will serve as the foundation for various investigational CAR-T therapies in the Novartis pipeline. With T-ChargeTM, we aim to go beyond incremental advances, and hope to revolutionize CAR-T offerings, with the goal of giving our patients improved outcomes.

Learn More
Immuno-oncology, a puzzle that needs to be solved

Solving the puzzle of immunotherapy

The question of how to unlock the potential of the body’s own immune system to kill cancer cells is more than a century old. For people with some solid tumors, significant progress has been made. For other patients, particularly those with blood cancers, immunotherapy options are extremely limited. At Novartis, we are building on insight upon insight to get closer to unlocking the potential of immunotherapies for more patients around the world.

Learn More
A doctor discusses different clinical trial options with a patient.

Relentlessly challenging the standard of care for patients with CML

More than 20 years of breakthrough innovation inspired by our patients has delivered new opportunities for people living with chronic myeloid leukemia (CML). Discover what has driven us to transform the standard of care for patients again, leading to the recent FDA approval for a novel therapy in CML.

Learn More
Mosaic of MDS related images

What could be possible if the immune system learns to fight back against MDS?

New understandings are paving the road for new possibilities in the treatment of myelodysplastic syndromes (MDS), a rare group of blood cancers. We are striving to help doctors show patients and caregivers how MDS affects the body by working alongside world-renowned artist Noma Bar and MDS advocates around the world; and researching how harnessing the immune system may play a role in the treatment of MDS.

Read More
Charlotte Curtis podcasts about SCD

Overcoming barriers to bold innovation in SCD

Understanding the complexities of sickle cell disease (SCD) is crucial to developing effective treatments for patients – from innovative chronic therapies targeting vaso-occlusive crises, the hallmark of the disease, to the potential of gene therapy.

 

After years of researching SCD and listening to the patient community, we’re equally committed to expanding access to diagnosis and treatment in the US and across the globe, as well as providing comprehensive support to help end health care disparities.

Read More
An engineer processes CAR-T cells in a laboratory

Stay up-to-date on Novartis Oncology news and stories.

Bold Bets for the Future

Driven by our passion for patients and grounded in our industry-leading oncology pipeline of more than 45 different compounds across 70+ development programs, we’re rapidly advancing novel treatment approaches in areas of great medical need, including melanoma, lung, and pancreatic cancer.

Our scientists are breaking through the barriers to transform cancer care and reimagine medicine.

"I believe we have a responsibility to keep pushing boundaries, to keep looking for that next transformative innovation, and rewrite the cancer story"

Susanne Schaffert, PhD, President of Novartis Oncology

A male patient sitting in a doctor’s office

Reimagining outcomes in prostate cancer with phenotypic precision medicine

Novartis is committed to exploring the full potential of radioligand therapy, one of our four therapeutic platforms, to transform patients’ lives. We are using bold science to research and develop new targeted treatments that address critical unmet needs in advanced prostate cancer.

Read the Press Release

Reimagining PROS

Novartis has a legacy of pursuing bold scientific approaches to solve serious challenges, from cancer to rare diseases. Now, we are striving to transform the lives of those affected by PIK3CA-Related Overgrowth Spectrum (PROS), a group of rare and potentially debilitating conditions.

Read the Press Release

Researching multiple approaches to improving the treatment landscape for patients with lung cancer

Worldwide, more people still die every year from lung cancer than from any other cancer. Bold science is urgently needed to help those living with lung cancer. From exploring targeted therapies, to the role interleukin-1 beta (IL-1β) may play in pro-tumor inflammation in lung cancer, and to potential new immuno- and radioligand treatments, our aspiration is to deliver potentially transformative medicines in lung cancer.

Learn More

Targeting Advanced Melanoma

As the established leader in targeted therapy for BRAF+ advanced melanoma, Novartis is proud to have played a role in reimagining the care of this life-threatening cancer. We have helped to transform the lives of nearly 200 000 people living with melanoma, and we remain dedicated to advancing science behind our targeted therapies to give patients the best chance for extended survival.

Learn More
Novartis President of Oncology Susanne Schaffert on a laptop

From Cancer to Cures

Our new monthly series "Let's Talk About the C Word: From Cancer to Cures" featuring President of Novartis Oncology Dr. Susanne Schaffert, addresses challenging cancer related topics.

Learn More

Recent Jobs in Oncology

When science and passion connect, innovation happe

When science and passion connect, innovation happe

Audit & Finance, USA, SANDOZ
Research & Development, USA, ONCOLOGY
Audit & Finance, Czech Republic, CTS
A Novartis scientist adjusting equipment in a drug research lab

Join our community.